Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 13/20 | 0.51 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31561507 | 1.00 | GPR119 (0.51) | GPR119HPGDEPHX1RECQL | |
| SCHEMBL14497251 | 0.92 | HPGD (0.45) | GPR119HPGDEPHX1RECQL | |
| SCHEMBL26100517 | 0.91 | GPR119 (0.53) | GPR119HPGDEPHX1RECQL | |
| SCHEMBL26099289 | 0.91 | GPR119 (0.53) | GPR119HPGDEPHX1RECQL | |
| SCHEMBL26098762 | 0.91 | GPR119 (0.53) | GPR119HPGDEPHX1RECQL | |
| SCHEMBL2881367 | 0.88 | GPR119 (0.55) | GPR119HPGDEPHX1RECQL | |
| SCHEMBL2881371 | 0.88 | GPR119 (0.55) | GPR119HPGDEPHX1RECQL | |
| SCHEMBL3784890 | 0.88 | GPR119 (0.55) | GPR119HPGDEPHX1RECQL | |
| SCHEMBL29026719 | 0.87 | NR1H2 (0.49) | GPR119HPGDEPHX1RECQL | |
| SCHEMBL21193938 | 0.87 | NR1H2 (0.49) | GPR119HPGDEPHX1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS INC (US) | 2026-04-02 | — | — | US | disclosed |
| US-20250122208-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2025-04-17 | — | — | US | disclosed |
| CN-119585256-A | Chemokine receptor modulators and uses thereof | 拉普特医疗公司 | 2025-03-07 | — | — | CN | disclosed |
| US-12240837-B2 | Chemokine receptor modulators and uses thereof | RAPT THERAPEUTICS, INC. (US) | 2025-03-04 | — | — | US | disclosed |
| EP-4504338-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT Therapeutics, Inc. (US) | 2025-02-12 | — | — | EP | disclosed |
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2023-10-12 | — | — | US | disclosed |
| WO-2023196432-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2023196432-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322741-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | GPR119 177/4885HPGD 437/4885EPHX1 440/4885 |
| US-20260092050-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | CCR1, CXCR2, CCR2 | GPR119 325/4885HPGD 3432/4885EPHX1 2027/4885 |
| US-12240837-B2 | Chemokine receptor modulators and uses thereof | ACKR3, CCR5, CXCR3 | GPR119 177/4885HPGD 437/4885EPHX1 440/4885 |
| US-20250122208-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | GPR119 272/4885HPGD 477/4885EPHX1 400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.